Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income	$ 27,551	$ 14,878
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	10,983	10,565
Bad debt provision	36,848	32,340
Deferred income taxes	(1,612)	(4,205)
Share-based compensation expense	6,828	6,793
Amortization of premium on marketable securities	1,003	1,609
Unrealized gain on deferred compensation fund investments	(7,809)	(2,562)
Changes in other long-term liabilities	(524)	(980)
Net loss on disposals of property and equipment	507	489
Share of losses from equity method investment	197	0
Changes in operating assets and liabilities:
Accounts and notes receivable	(57,909)	(59,530)
Inventories and supplies	1,434	1,976
Prepaid expenses and other assets	(3,503)	8,620
Deferred compensation funding	(27)	(353)
Accounts payable and other accrued expenses	(10,904)	(4,276)
Accrued payroll, accrued and withheld payroll taxes	(12,820)	(16,118)
Income taxes payable	(2,700)	(4,543)
Accrued insurance claims	(1,348)	6,207
Deferred compensation liability	8,403	3,143
Net cash used in operating activities	(5,402)	(5,947)
Cash flows from investing activities:
Disposals of property and equipment	193	121
Additions to property and equipment	(4,909)	(3,973)
Acquisition of equity method investment	(2,750)	0
Purchases of marketable securities	(51,490)	0
Sales of marketable securities	43,205	1,942
Net cash used in investing activities	(15,751)	(1,910)
Cash flows from financing activities:
Purchases of treasury stock	(4,008)	(6,239)
Proceeds from short-term borrowings	0	20,000
Payments of statutory withholding on net issuance of restricted stock units	(1,030)	(870)
Net cash (used in) provided by financing activities	(5,038)	12,891
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents	(26,191)	5,034
Cash, cash equivalents and restricted cash equivalents at beginning of the period	54,330	26,279
Cash, cash equivalents and restricted cash equivalents at end of the period	$ 28,139	$ 31,313